Progress in the Treatment of Topical Rapamycin Preparations
10.12376/j.issn.2097-0501.2023.02.013
- VernacularTitle:外用雷帕霉素制剂的应用进展
- Author:
Senfen WANG
1
;
Yuanxiang LIU
2
;
Zigang XU
2
Author Information
1. Department of Dermatology, Shenzhen Children's Hospital, Shenzhen 518026, China.
2. Department of Dermatology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China.
- Publication Type:Journal Article
- Keywords:
rapamycin;
sirolimus;
tuberous sclerosis complex;
vascular malformation
- From:
JOURNAL OF RARE DISEASES
2023;2(2):273-280
- CountryChina
- Language:Chinese
-
Abstract:
Rapamycin is a mammalian target of rapamycin(mTOR) receptor inhibitor. Advances in the understanding of the mTOR signaling pathway and its downstream effects on tumorigenesis and vascular proliferation have broadened the clinical applications of mTOR receptor inhibitors in treating many challenging diseases. Rapamycin is used orally for the treatment of kidney transplantation, lymphatic leiomyomatosis of lung, tuberous sclerosis complex(TSC), and etc. But systemic therapy using the rapamycin has significant side effects. To mitigate the side effects of systemic rapamycin for dermatologic applications, clinicians have used topical therapy. In recent years, research publications on the topical rapamycin in the treatment of a variety of diseases have increased, as on such diseases of facial angiofibroma of tuberous sclerosis complex, lymphatic malformation, Kaposi hemangioendothelioma, tufted angiomas, and etc. Topical rapamycin can be used as an effective long-term therapy while avoiding systemic side effects, providing a new treatment method for dermatologists. This paper discusses the progress in the treatment of topical rapamycin preparations.
